Nova Scotia Health Authority

Running trials

• Not yet recruiting

  A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity

  NCT07919405· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

  NCT07028853· Phase 3· Pfizer· Source

• Active, not recruiting

  A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

  NCT07076199· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

  NCT06858878· Phase 3· Amgen· Source

• Recruiting

  Sustainable Implementation of the EXCEL Exercise Oncology Program Across Canada

  NCT06960291· University of Calgary· Source

• Active, not recruiting

  A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

  NCT06780449· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  NCT05554406· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

  NCT06567743· Phase 2· CG Oncology, Inc.· Source

• Recruiting

  Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  NCT05554393· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

  NCT06226883· Phase 2· Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)· Source

• Recruiting

  Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma

  NCT06124976· Phase 2/3· Peter Black· Source

• Recruiting

  MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  NCT05564390· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  RAFT - Pace &Ablate

  NCT06299514· Habib Khan· Source

• Recruiting

  Tracking Results of Ablations to Combat AF Registry Generation 2

  NCT05111015· AtriCure, Inc.· Source

• Recruiting

  A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

  NCT06233461· Phase 2· Takeda· Source

• Active, not recruiting

  A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

  NCT06208150· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  An Innovative Master Platform for Clinical Trials in Mood Disorders

  NCT06408012· St. Joseph's Healthcare Hamilton· Source

• Recruiting

  Left vs Left Randomized Clinical Trial

  NCT05650658· Baylor College of Medicine· Source

• Active, not recruiting

  A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

  NCT05884398· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

  NCT05714202· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)

  NCT05017311· Phase 4· Nova Scotia Health Authority· Source

• Recruiting

  A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

  NCT05623020· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease

  NCT05347095· Phase 3· Janssen-Cilag Ltd.· Source

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05242484· Phase 2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT05242471· Phase 2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

  NCT05316155· Phase 1/2· Janssen Research & Development, LLC· Source

• Recruiting

  Cohort Study - SBRT for VT Radioablation

  NCT04162171· John Sapp· Source

• Active, not recruiting

  Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

  NCT04821622· Phase 3· Pfizer· Source

• Recruiting

  LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

  NCT04752722· Phase 1/2· enGene, Inc.· Source

• Recruiting

  Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  NCT04269902· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment

  NCT04647526· Phase 3· POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company· Source

• Recruiting

  Brain Imaging Study on Biomarkers for Fibromyalgia

  NCT03910010· Nova Scotia Health Authority· Source

• Active, not recruiting

  Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

  NCT04340141· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis

  NCT04217356· University Health Network, Toronto· Source

• Recruiting

  Genetic Counselling in the Prevention of Mental Health Consequences of Cannabis Use

  NCT03601026· Nova Scotia Health Authority· Source

• Active, not recruiting

  Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

  NCT03907488· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

  NCT03767244· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance

  NCT03536312· Ottawa Heart Institute Research Corporation· Source

• Active, not recruiting

  Characterization of Arrhythmia Substrate to Ablate Persistent Atrial Fibrillation

  NCT03347227· Ottawa Heart Institute Research Corporation· Source

• Recruiting

  Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  NCT03150693· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

  NCT03055013· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  Personalized Indications for CBT and Antidepressants in Treating Depression

  NCT02752542· Phase 4· Nova Scotia Health Authority· Source

• Active, not recruiting

  Comprehensive Segmental Revision System

  NCT03270982· Zimmer Biomet· Source

• Recruiting

  The Canadian Depression Research and Intervention Network (CDRIN) Maritimes Registry

  NCT02443636· Nova Scotia Health Authority· Source

• Active, not recruiting

  Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

  NCT02003222· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  Skills for Wellness

  NCT01980147· Nova Scotia Health Authority· Source

• Active, not recruiting

  Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

  NCT01886872· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

  NCT01841736· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

  NCT01574053· CHDI Foundation, Inc.· Source

Showing 50 of 53.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Bipolar disorder4 recruiting
• Depression4 recruiting
• Acute myeloid leukaemia3 recruiting
• Bladder cancer3 recruiting
• Heart failure3 recruiting
• Atrial fibrillation2 recruiting
• Crohn's disease2 recruiting
• Myelodysplastic syndromes2 recruiting
• Myeloproliferative neoplasms2 recruiting
• Schizophrenia2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Amyloidosis1 recruiting
• Aortic aneurysm1 recruiting
• Colorectal cancer1 recruiting
• Coronary artery disease1 recruiting
• Fibromyalgia1 recruiting
• High blood pressure1 recruiting
• Huntington's disease1 recruiting
• Lung cancer1 recruiting
• Multiple myeloma1 recruiting
• Obesity1 recruiting
• Prostate cancer1 recruiting
• Ventricular tachycardia1 recruiting

Closed trials

• Completed

  A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight

  NCT06388187· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Participants With Non-Small Cell Lung Cancer

  NCT06068842· AbbVie· Source

• Completed

  STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease

  NCT05843578· Phase 2· Agomab Spain S.L.U.· Source

• Completed

  A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)

  NCT05646706· Phase 3· Novo Nordisk A/S· Source

• Completed

  Piloting of an Intervention to Reduce Problematic Alcohol Use in Early Phase Psychosis Patients

  NCT05365347· Nova Scotia Health Authority· Source

• Completed

  IBD Neoplasia Surveillance RCT

  NCT05809999· Ottawa Hospital Research Institute· Source

• Completed

  Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

  NCT04471844· NovoCure Ltd.· Source

• Completed

  EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)

  NCT03950076· Phase 4· Population Health Research Institute· Source

• Completed

  A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)

  NCT03976362· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

  NCT03924856· Phase 3· Merck Sharp & Dohme LLC· Source

• Terminated

  WAVe Study - Weight Adjusted Dalteparin for Patients Over 90 kg With Acute Cancer Associated Venous Thromboembolism

  NCT03297359· Phase 2· Ottawa Hospital Research Institute· Source

• Completed

  Antiarrhythmics or Ablation for Ventricular Tachycardia 2

  NCT02830360· Phase 4· John Sapp· Source

• Completed

  Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial

  NCT02089217· Mayo Clinic· Source

• Completed

  LOWER: Lomitapide Observational Worldwide Evaluation Registry

  NCT02135705· Amryt Pharma· Source

• Completed

  Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

  NCT00324805· Phase 3· National Cancer Institute (NCI)· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Fibromyalgia5 works · 1 trial
• Fabry disease3 works · 0 trials